Navigation Links
StromAb, First-In-Class Antibody Dissolves Thrombus In ACUTE Stroke & Cardiovascular Disease, In Production Phase I Clinical Trials
Date:11/21/2013

(PRWEB) November 21, 2013

Translational Sciences Inc. announces that StromAb is in production on Phase I Clinical Trials. Production began after completing highly successful pre-clinical development studies showing exceptional efficacy and safety in multiple disease models.

StromAb is a first-in-class antibody providing immediate safe dissolution of ACUTE blood clots that cause > 2 million cases of ischemic stroke, venous thrombosis, pulmonary embolism, heart attack and acute peripheral vascular ischemia in the U.S. alone.

Translational Sciences Inc. holds exclusive licensing rights with Massachusetts General Hospital & Harvard University.

Distinct from existing agents or agents in development: StromAb occupies a different therapeutic space, than anticoagulants (e.g., heparins, or direct thrombin or factor Xa inhibitors etc.). StromAb rapidly dissolves clots in ACUTE cardiovascular diseases; anticoagulants inhibit blood clot formation but do not dissolve clots.

However, StromAb is also compatible with anticoagulants in the therapeutic process.

StromAb was selected by NIH for therapeutic development grants. StromAb is supported by multiple patents and patent actions.

Translational Sciences is currently exploring partnerships for future clinical trials.

Experts Have Commented:

  •     “The striking preclinical profile of StroMAb .…predicts both a significant improvement in efficacy and major reductions in risk….could revolutionize the treatment of ischemic stroke.”
  •     “This is a highly significant project that addresses the most important unmet medical need for safe drugs to treat acute thrombotic diseases with poor prognosis (stroke, heart attack, pulmonary embolism, arterial thrombosis)."
  •     “These antibodies have the potential to dramatically change the course of treatment of thromboembolic stroke and other ischemic diseases.”

Translational Sciences, Inc. is a privately held biopharmaceutical company that translates scientific insights into first-in-class, biologic agents for cardiovascular diseases.

Interested parties may contact Translational Sciences at 901-274-4506 or email David Pedersen, dpedersen(at)translationalsciences(dot)com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11351177.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug
2. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
3. Labome: The Gateway to the Perfect Antibody -- Labome Antibody Review Database Has Now Reached 10,000 Peer-Reviewed Formal Publications
4. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
5. Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment
6. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
7. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
8. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
9. Goodwin Biotechnology and Coldstream Laboratories Announce a Collaboration to Develop and Manufacture Cytotoxic Antibody Drug Conjugates
10. Scripps Research Institute Scientists Find Antibody that Transforms Bone Marrow Stem Cells Directly into Brain Cells
11. Antibody Technologies and Attrition Rates -- an industry analysis 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):